Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1
In this study, we investigated the effect and mechanism of Resibufogenin on renal cell carcinoma based on network pharmacology, molecular docking, and in vitro experiments. The results showed that there were 35 cross-targets between Resibufogenin and renal cell carcinoma. GO and KEGG pathway analyse...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/13/12/1064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850240162977546240 |
|---|---|
| author | Yuqi Wu Yue Yang Run Huang Tao Li Chunlei Wan Lei Zhang |
| author_facet | Yuqi Wu Yue Yang Run Huang Tao Li Chunlei Wan Lei Zhang |
| author_sort | Yuqi Wu |
| collection | DOAJ |
| description | In this study, we investigated the effect and mechanism of Resibufogenin on renal cell carcinoma based on network pharmacology, molecular docking, and in vitro experiments. The results showed that there were 35 cross-targets between Resibufogenin and renal cell carcinoma. GO and KEGG pathway analyses indicated that Resibufogenin inhibited renal cancer cells through the vascular smooth muscle contraction signalling pathway and EGFR tyrosine kinase inhibitor resistance signaling pathway, and MAPK1, PRKCB, and Resibufogenin had strong associative activities. After different concentrations of Resibufogenin were applied to human renal cancer cells, it was found that the IC50 value was 408.2 nM, 10 nM resibufogenin could significantly inhibit cell migration (<i>p</i> < 0.0001), the percentage of apoptosis and necrosis increased dose-dependently, and the expression of genes of MAPK1 and PRKCB in the cells was significantly reduced (<i>p</i> < 0.001) in a dose-dependent manner. The above results indicate that Resibufogenin can inhibit human renal cell carcinoma through multi-targets and multi-methods, which provides a theoretical basis for the application of Resibufogenin in the treatment of renal cell carcinoma and the development of novel drugs in the future. |
| format | Article |
| id | doaj-art-cf49c5a7339d4d9d9c1e227578b062c2 |
| institution | OA Journals |
| issn | 2079-7737 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj-art-cf49c5a7339d4d9d9c1e227578b062c22025-08-20T02:00:55ZengMDPI AGBiology2079-77372024-12-011312106410.3390/biology13121064Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1Yuqi Wu0Yue Yang1Run Huang2Tao Li3Chunlei Wan4Lei Zhang5School of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, ChinaIn this study, we investigated the effect and mechanism of Resibufogenin on renal cell carcinoma based on network pharmacology, molecular docking, and in vitro experiments. The results showed that there were 35 cross-targets between Resibufogenin and renal cell carcinoma. GO and KEGG pathway analyses indicated that Resibufogenin inhibited renal cancer cells through the vascular smooth muscle contraction signalling pathway and EGFR tyrosine kinase inhibitor resistance signaling pathway, and MAPK1, PRKCB, and Resibufogenin had strong associative activities. After different concentrations of Resibufogenin were applied to human renal cancer cells, it was found that the IC50 value was 408.2 nM, 10 nM resibufogenin could significantly inhibit cell migration (<i>p</i> < 0.0001), the percentage of apoptosis and necrosis increased dose-dependently, and the expression of genes of MAPK1 and PRKCB in the cells was significantly reduced (<i>p</i> < 0.001) in a dose-dependent manner. The above results indicate that Resibufogenin can inhibit human renal cell carcinoma through multi-targets and multi-methods, which provides a theoretical basis for the application of Resibufogenin in the treatment of renal cell carcinoma and the development of novel drugs in the future.https://www.mdpi.com/2079-7737/13/12/1064Resibufogeninrenal cell carcinomanetwork pharmacology |
| spellingShingle | Yuqi Wu Yue Yang Run Huang Tao Li Chunlei Wan Lei Zhang Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 Biology Resibufogenin renal cell carcinoma network pharmacology |
| title | Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 |
| title_full | Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 |
| title_fullStr | Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 |
| title_full_unstemmed | Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 |
| title_short | Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1 |
| title_sort | effectiveness and mechanism of resibufogenin on human renal cancer cell caki 1 |
| topic | Resibufogenin renal cell carcinoma network pharmacology |
| url | https://www.mdpi.com/2079-7737/13/12/1064 |
| work_keys_str_mv | AT yuqiwu effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 AT yueyang effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 AT runhuang effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 AT taoli effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 AT chunleiwan effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 AT leizhang effectivenessandmechanismofresibufogeninonhumanrenalcancercellcaki1 |